Dhruv Jani sells 6,78,000 Global Longlife shares, stake drops to 16.41%

1 min read     Updated on 03 Aug 2026, 12:42 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Dhruv Sureshkumar Jani sold 6,78,000 shares of Global Longlife Hospital and Research Ltd via open market trades in July 2026. His promoter stake fell from 22.87% to 16.41%. The disclosure was filed under SEBI Regulation 29(2) on August 1, 2026.

powered bylight_fuzz_icon
47286748

*this image is generated using AI for illustrative purposes only.

Promoter Dhruv Sureshkumar Jani has reduced his stake in Global Longlife Hospital and Research by selling 6,78,000 equity shares on the open market. The sales, executed between July 01, 2026, and July 30, 2026, lower his holding from 22.87% to 16.41%, marking a significant dilution in promoter ownership during the month.

The disclosure was filed with BSE Limited on August 01, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirms that the seller belongs to the promoter group and that the transactions were conducted via the open market rather than through block deals or off-market transfers.

Transaction Details

The sale represents a reduction of 6.46% in the company's total share capital. Prior to the transaction, Jani held 24,00,990 voting rights, which constituted 22.87% of the total diluted share/voting capital. Following the sale, his holding stands at 17,22,990 shares, representing 16.41% of the total capital.

Metric Before Sale Sale Details After Sale
Shares Held 24,00,990 6,78,000 17,22,990
Stake (%) 22.87% 6.46% 16.41%
Mode N/A Open Market N/A

The company’s total equity share capital remains unchanged at ₹10,50,00,000, comprising 1,05,00,000 equity shares of ₹10 each. There were no changes in voting rights acquired or sold otherwise than by shares, nor any warrants or convertible securities involved in the transaction.

What the Numbers Show

The reduction in promoter stake from 22.87% to 16.41% is material, indicating a deliberate exit strategy or liquidity requirement by the promoter. With no encumbrances such as pledges or liens reported in the filing, the shares sold were unencumbered assets. The open market mode suggests the sales were likely executed in smaller tranches to minimize price impact, a common practice for substantial holdings.

Historical Stock Returns for Global Longlife Hospital & Research

1 Day5 Days1 Month6 Months1 Year5 Years
+0.77%-3.36%-0.34%-23.39%-48.13%-91.29%

What is the primary motivation behind Dhruv Sureshkumar Jani's significant stake reduction, and does it signal a lack of confidence in Global Longlife's future growth prospects?

How might this 6.46% dilution in promoter ownership impact the stock's liquidity and volatility in the short term, given the open market execution method?

Are there indications of new institutional or foreign investors acquiring these shares, and could this shift in shareholder structure influence corporate governance decisions?

Global Longlife Hospital & Research
View Company Insights
View All News
like16
dislike

Global Longlife Hospital appoints Hiren Mandaliya as Independent Director

1 min read     Updated on 26 Jun 2026, 05:04 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Global Longlife Hospital and Research Ltd announced the appointment of Hiren Mandaliya as a Non-Executive Independent Director for a five-year term from March 31, 2026, to March 30, 2031. The appointment was approved by shareholders at the Annual General Meeting on June 25, 2026. Mandaliya, a Chartered Accountant, brings expertise in accounting and taxation.

powered bylight_fuzz_icon
44019260

*this image is generated using AI for illustrative purposes only.

Global Longlife Hospital and Research Ltd has appointed Hiren Mandaliya as a Non-Executive Independent Director for a period of five years. The appointment, effective from March 31, 2026, to March 30, 2031, was approved by shareholders at the Annual General Meeting held on June 25, 2026, based on the recommendation of the Board of Directors.

Mandaliya is a qualified Chartered Accountant with expertise in accounting, taxation, compliances, finalization of accounts, filing of returns, assessment proceedings, and representation before tax authorities. The disclosure confirms that he is not related to any director of the company and is not debarred from holding the position of director by any SEBI order or other authority.

The appointment was disclosed to the BSE under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided the necessary details in accordance with Schedule III of the SEBI LODR Regulations and the relevant SEBI Master Circular.

Appointment Details

Detail Information
Name of Director Mr. Hiren Mandaliya
DIN 11636452
Designation Non-Executive Independent Director
Date of Appointment June 25, 2026
Term of Office Five Years (March 31, 2026 to March 30, 2031)
Qualification Chartered Accountant

Historical Stock Returns for Global Longlife Hospital & Research

1 Day5 Days1 Month6 Months1 Year5 Years
+0.77%-3.36%-0.34%-23.39%-48.13%-91.29%

How will Mr. Mandaliya's financial expertise influence the company's future fiscal strategies and cost management?

What specific governance improvements can shareholders expect following the addition of this independent director?

Does this appointment signal a shift in the company's focus towards stricter regulatory compliance and transparency?

Global Longlife Hospital & Research
View Company Insights
View All News
like16
dislike

More News on Global Longlife Hospital & Research

1 Year Returns:-48.13%